Cancer 101
Not yet a member?
Today CNN.com published an article detailing a lawsuit by the American Civil Liberties Union, in partnership with Yeshiva University law school, arguing that patents for the human genes BRCA1 and BRCA2 are unconstitutional.
Just to give some background, BRCA (BReast CAncer) 1 and 2 are genes that are associated with hereditary breast and ovarian cancer, and [...]
One of the things that I found regrettable about the parallel universes in which information is provided for doctors vs. other information for patients is that there is a different language and frame of understanding that is used for these separate conversations. Patients may be seeking opportunities and don’t need incontrovertible evidence that a fourth or [...]
4 CommentsAlthough there are many controversial topics in the management of lung cancer, it’s hard to think of another issue that incites emotion as much as the debate about lung cancer screening. After describing some of the pitfalls and arguments made by detractors in a prior post well over a year ago, I received multiple impassioned comments [...]
2 CommentsI have a remarkably delightful patient who initially developed a stage I NSCLC in 1998, and this was treated with standard surgery. Three years later, she was found on a routine follow-up scan to have disease in her mediastinum. This was biopsied and was found to look remarkably like her original cancer [...]
0 CommentsI’ve had a series of questions about how frequent follow-up should be for LC after surgery for early stage disease, or potentially after chemo and radiation for stage III disease. The most appropriate answer to to say that there is really essentially no data on this subject, so people have made [...]
2 CommentsAlthough in the last few years there has been a greater focus on low molecular weight heparins (LMWHs), which are injected, the oral anticoagulant (blood thinner) has been studied in this capacity and is certainly widely used in clinical practice for patients with blood clots due to its oral administration, which is [...]
0 CommentsOver the past several years, oncologists have experienced an evolution in the way we think about stable disease, at least in the context of lung cancer. Historically, oncologists have graded our work by looking at response rates, or the percentage of patients with tumor shrinkage of 50% or more of their [...]
6 CommentsToday we cannot predict the behavior of individal patient tumors and need to overtreat some patients and undertreat others. However, the science behind lung cancer has now moved a step forward by identifying a “molecular signature” of key genes that may predict patient survival. This week’s New England Journal of Medicine [...]
0 Comments
GRACE Home
| Forums
| About GRACE
| 
Donate
| GRACE Website Tutorial
| Contact
| Terms Of Use
Disclaimer: The information provided at GRACE is for informational purposes only. The faculty of GRACE is not providing medical advice, diagnosis or treatment and cannot replace the medical advice of your doctor or health care provider. (Full Disclaimer)
© 2007-2010 GRACE. All rights reserved.
